What was filed
Jagsonpal Pharmaceuticals filed its press release and investor presentation for the unaudited results for the quarter ended 30 June 2026 (Q1 FY27). Alongside the quarterly numbers, the filing details two capital-allocation actions the company said it completed during the quarter: the acquisition of a controlling stake in Aequitas Healthcare and a share buyback. The company said revenue, operating EBITDA and profit all rose year on year, with margins expanding.
The quarter's operating story
Per the filing, the company attributed growth to higher medical-representative (MR) productivity and continued strength across key brands. It said it grew faster than the broader market, citing Pharmarack data of 18.9% growth for Jagsonpal versus 11.6% for the Indian Pharmaceutical Market, and an improvement of four ranks to #88. Margin expansion was described as driven by operating leverage rather than one-off gains, and the company said its cash position held up despite the buyback outflow.
The Aequitas acquisition
The filing frames Aequitas as the company's entry into the hospital-supplies business. Jagsonpal said it acquired an 85% controlling stake in an all-cash deal funded from internal accruals, making Aequitas a subsidiary while existing promoters retain 15%. Per the filing, Aequitas is a seven-year-old, Mumbai-headquartered specialty player with relationships across 1,000+ hospitals and 4,000+ doctors. The company said it is targeting EBITDA of over ₹100 Mn from the acquired business by Year 2 post-integration, with higher contribution and profitability expected from H2 FY27 onwards.